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A B S T R A C T
African swine fever virus (ASFV) causes serious disease in domestic pigs for which there is no vaccine currently
available. ASFV is a large DNA virus that encodes for more than 150 proteins, thus making the identification of
viral antigens that induce a protective immune response difficult. Based on the functional roles of several ASFV
proteins found in previous studies, we selected combinations of ASFV recombinant proteins and pcDNAs-ex-
pressing ASFV genes, to analyze their ability to induce humoral and cellular immune responses in pigs.
Pigs were immunized using a modified prime-boost approach with combinations of previously selected viral
DNA and proteins, resulting in induction of antibodies and specific cell-mediated immune response, measured by
IFN-γ ELISpots. The ability of antibodies from pigs immunized with various combinations of ASFV-specific
antigens to neutralize infection in vitro, and antigen-specific activation of the cellular immune response were
analyzed.
1. Introduction
Virulent isolates of African swine fever virus (ASFV), a large, en-
veloped DNA virus (Tulman et al., 2009), cause an acute hemorrhagic
fever in domestic pigs which usually die in fewer than twelve days post-
infection. Due to the lack of effective vaccines, African swine fever
(ASF) is considered one of the most significant and devastating viral
diseases of domestic pigs (Sanchez-Vizcaino et al., 2013).
Recent outbreaks reported in Caucasus countries, Russia and
Eastern Europe highlight the urgent need to develop effective vaccines
against ASFV. Unfortunately, the development of an effective, safe
ASFV vaccine is a complex objective and has so far been unsuccessful.
Nevertheless, pigs surviving ASFV infection develop a strong protective
immunity, indicating that an effective vaccine against ASFV may be
possible.
The use of inactivated viruses and ASFV subunits (viral DNA or
proteins) as vaccines represents a safe possibility; however, inactivated
preparations of ASFV have not conferred protection so far, even in the
presence of adjuvants (Blome et al., 2014). While vaccine strategies
based on the expression of ASFV proteins seem to favor the generation
of neutralizing antibodies (NAbs) in the vaccinated animals, the com-
bination of recombinant proteins with plasmid DNA expressing ASFV
antigens has not been approached. Passive transfer of ASFV antibodies
protected pigs against a lethal ASFV challenge (Onisk et al., 1994),
demonstrating the potential protective properties for specific anti-
bodies, although there is controversy about the role of antibody-
mediated neutralization of ASFV (Escribano et al., 2013). Several ASFV
proteins have been reported to induce neutralizing antibodies in im-
munized pigs, including the proteins p72, p54 and p32 (also called p30)
(Gomez-Puertas et al., 1998, 1996). However, pigs immunized with p54
and p32 recombinant baculovirus-expressed proteins were not pro-
tected against lethal infection (Gomez-Puertas et al., 1998). In the same
line, a vaccine based on the expression of the ASFV proteins p30, p54,
p22 and p72 in baculovirus was able to produce neutralizing antibodies
but failed to protect pigs from a virulent challenge (Neilan et al., 2004).
In contrast, the ASFV hemaglutinine (HA) protein (EP402R, also named
CD2v) when functionally expressed in a baculovirus system, showed
some degree of protection against a virulent challenge (Ruiz-Gonzalvo
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et al., 1996).
Strategies based on DNA vaccines have been also performed
(Argilaguet et al., 2011, 2012) and immunization with a DNA expres-
sion library excluding viral CD2v, p30/p32 and p54 conferred partial
protection against virulent challenge (Lacasta et al., 2014). Further-
more a very recent work showing the immunization of pigs by DNA-
prime and recombinant vaccinia virus-boost to identify ASFV im-
munogenic and protective proteins has been reported (Jancovich et al.,
2018). From these studies several immunogenic ASFV antigens have
been identified, but a proper combination of these or still non-described
antigens that are able to confer full protection has yet to be elucidated.
In order to contribute to the development of a future subunit vac-
cine, we have here studied the combination of specific recombinant
ASFV proteins and plasmid-expressing viral DNAs, with the aim to
enhance both the humoral and cellular immune responses. Pigs were
immunized three times using a prime-boost approach with various
combinations of viral DNA and proteins, resulting in production of
antibodies, some of which were proven to be partially neutralizing in
vitro. In addition, the specific cell-mediated immune response was
measured by IFN-γ ELISpot assays to identify the combination of anti-
gens inducing the best interferon responses.
2. Materials and methods
2.1. Cells and virus
Vero and COS-7 cells (both derived from African green monkey
kidneys) were obtained from the American Type Culture Collection
(ATCC) to use for virus propagation. Cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 2mM L-gluta-
mine, 100 U/ml gentamicin, nonessential amino acids, and 5% fetal
bovine serum (FBS; Invitrogen Life Technologies), and maintained at
37 °C under a 5% CO2 atmosphere saturated with water vapor.
The Vero-adapted ASFV strain Ba71 V and virulent strain E70 were
propagated on Vero and COS-7 cells, as described previously
(Carrascosa et al., 1982; Enjuanes et al., 1976). In brief, sub-confluent
monolayers were cultivated in cell culture treated roller bottles and
infected with ASFV at a multiplicity of infection (MOI) of 0.5 in culture
medium. At 72 h post infection, cells were pelleted and the supernatant
recovered. The supernatant containing viruses was centrifuged at
14,000 rpm for 6 h at 4 °C and the purified infectious virus was re-
suspended in medium and stored at −80 °C.
2.2. Nascent virus for neutralization assays
Vero cells were infected with ASFV strain Ba71 V at a MOI of 1 pfu/
cell. After 24 h, infected cells were softly recovered with a cell scraper
and centrifuged at 1000 rpm for 5min. The supernatant was discarded
and cells were washed once with media supplemented with 10% FBS
and incubated at 37 °C for 1 h in media with FBS. After this period, cells
were centrifuged at 2000 rpm for 10min and the supernatant was fil-
tered using a filter with a 0.45 μm pore. The virus obtained by this
procedure was titrated and used for neutralization assays.
2.3. ASFV infection assays
Vero and COS-7 cells were mock- infected or infected with ASFV
strains Ba71 V or E70 at different MOI in DMEM supplemented with 2%
FBS. During an adsorption period of 90min at 37 °C, the virus was re-
moved and cells were incubated at 37 °C. In the case of neutralization
for entry assays, the viral infection time was 30min at 37 °C (without
adsorption) and cells were processed.
2.4. Generation of ASFV recombinant proteins
The full-length open reading frame (ORF) of CP530R (coding for the
proteins p15 and p35), E183 L (coding for p54), 1-621bp of EP402R
(coding for the extracellular domain of CD2v (Goatley and Dixon,
2011)), B646 L (coding for p72) and CP204 L (coding for p32) were
synthesized based on ASFV isolate Georgia/2007 (GeneBank:
FR682468.1) and cloned into a common plasmid vector (e.g. pUC57,
GENEWIZ). ASFV proteins p15, p35, p54 and CD2v-E were expressed in
baculoviruses using the BaculoDirect expression system (Invitrogen).
ASFV protein p32 was expressed in Escherichia coli using the pET101/D-
TOPO E. coli expression system (Invitrogen).
For Baculovirus expression, individual ASFV genes were cloned into
the pENTR/D-TOPO vector (Invitrogen). The donor plasmids were in-
cubated with LR Clonase II and BaculoDirect linearized baculovirus
DNA. To produce recombinant baculoviruses, generated DNAs were
transfected into Spodoptera frugiperda 9 (SF9) cells using Cellfectin II
reagent (Invitrogen) and then recombinant baculovirus was selected
using 100 μM of Ganciclovir. Infected cells were cultured for 72 h and
cell pellets were collected for protein purification. The CP204 L gene
(p32) was cloned into a pET101/D-TOPO vector (Invitrogen) for E. coli
expression. The TOPO cloning reactions were transformed into One
Shot Top10 chemically competent E. coli (Invitrogen). The plasmid p32-
pET101 was transformed into BL21 competent E.coli and then cultured
for protein expression and purification. The integrity and correct or-
ientation of the recombinant gene was confirmed by PCR and DNA
sequencing.
Recombinant proteins with histidine tags were purified via affinity
chromatography using Ni-NTA superflow resin (Qiagen) after lysis of
cells under native condition. The lysis of cells under native condition
was performed on cell pellets resuspended in 50mM sodium phosphate,
500mM sodium chloride, 10mM imidazole, 5% glycerol, 400 units
benzonase nuclease per 1 g of pellet (pH 8.0), followed by two freeze/
thaws and 6 short (10 s) sonications. The lysate was centrifuged at
10,000 rpm, at 4 °C for 20min. Supernatant was used for Ni-NTA resin
purification. Purified proteins were dialyzed against phosphate buffered
saline (pH 7.4, 150mM NaCl, 4 mM EDTA, 10% glycerol). Purification
of ASFV proteins were confirmed via Coomassie blue staining of SDS-
PAGE gels and western blots. Protein concentrations were determined
using the bicinchoninic acid (BCA) assay (Thermo Scientific) at an
absorbance of 562 nm, using bovine serum albumin (Sigma-Aldrich) as
the protein standard.
2.5. Generation of pcDNA 3.1 plasmids expressing ASFV-specific genes
Overlap PCR was used to insert the full-length EP402R gene (coding
for CD2v), CP204 L (coding for p32), B646 L (coding for P72), CP312R
into pcDNA 3.1 (Invitrogen) adding the following restrictions sites to
the amplification primers: a BamHI site to the 5′ end and an EcoRI site
to the 3′ end of EP402R; a BamHI site to the 5′ end and an EcoRI site to
the 3′ end of CP204 L; a BamHI site to the 5′ end and an XhoI site to the
3′ end of B646 L; and a SmaI site to the 5′ end and an EcoRI site to the 3′
end of CP312R. The fragments were amplified by PCR from a lysate of
cells infected either by ASFV E70 or Ba71 V, using the following pri-
mers: 5′- CGCGCGGGATCCATGATAATAATAGTTATTTTTTTAATGTG
-3′ and 5′-CGCGCGGAATTCTTAAATAATTCTATCTACATGAATAAGCG
-3′ for EP402R; 5′-GGGGGGGAGTCCGTTATGGATTTTATTTTAAAT -3′
and 5′- CGCCGCCTCGAGCTAAAACATTAAATGTAGGTGA -3′ for
CP204 L; 5′-GCGCGGATCCATGGCATCAGGAGGAGCTTTTTGTC-3′ and
5′-CGCGCTCGAGTTAGGTACTGTAACGCAGCACAGCTG-3′ for B646 L;
and 5′-GGGCCCGGGGATGTTACTAGTAAAAATGACT -3′ and 5′-GGGG
GAATTCTTATTAAGCAATAGCGATCTG-3′ for CP312R. PCR products
and pcDNA vector were digested with the corresponding restriction
enzymes and ligated with T4 ligase (Roche). Products were transformed
into E. coli DH5α by heat shock. Correctness of respective plasmid
construct was confirmed by DNA sequencing and blast analysis. The
ORF D250R (Ba71 V)-g5R (Malawi), that encodes a decapping protein
(ASFV-DP) which has a Nudix hydrolase motif and decapping activity in
vitro was generated following a similar strategy as described previously
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(Quintas et al., 2017).
2.6. Ethics statement
All animal studies were performed under an Institutional Animal
Care and Use Committee-approved protocol of Kansas State University
in compliance with the Animal Welfare Act. The animal studies were
carried out at the Large Animal Research Center (Biosafety level 2 fa-
cility) and the biosecurity research institute (Biosafety level 3 facility)
at Kansas State University, Manhattan, KS, USA.
2.7. Animals and experimental design
2.7.1. First experiment
Forty conventional three-week old piglets were acclimated for one
week and divided into 8 groups with 5 pigs per group (group 1 A to
group 1 H). Pigs were immunized with a combination of different re-
combinant proteins and pcDNA constructs, depending on the group, as
shown in Table 1. Specifically, piglets were inoculated intramuscularly
(IM) with 100 μg of the respective recombinant protein in ISA 25 ad-
juvant (SEPPIC) and/or 100 μg of the respective pcDNA construct.
Piglets were vaccinated three times at two-week intervals (days 0, 14
and 28). One week after the last immunization on day 35 post initial
immunization (dpi), pigs were humanely euthanized by intravenous
injection of appropriate concentration of pentobarbital sodium. Blood
was collected on the days of immunization and prior to euthanasia.
2.7.2. Second experiment
Thirty conventional three-week old piglets were randomly divided
into 6 groups (group 2 A to group 2 F, Table 2), with 5 pigs per group.
Piglets were acclimated and housed the same as described for the first
animal study. Piglets were inoculated IM with 100 μg of the respective
recombinant protein mixed with ISA25 adjuvant (SEPPIC) and 100 μg
of each pcDNA construct, as it is shown in Table 2. Piglets were im-
munized three times at 0, 21 and 35 dpi. Blood was collected on the
days of vaccination and prior to euthanasia, which occured at 49 dpi.
2.8. Assessment of immunogenicity
2.8.1. Antibody detection in serum by ELISA tests
ELISAs were performed by using the recombinant ASFV proteins as
antigens. Briefly, wells were coated with 200 ng of the respective re-
combinant ASFV protein in 100 μl of PBS 1X and incubated overnight at
4 °C. Sera from immunized pigs were incubated at dilutions of 1/20 and
1/200 in 100 μl of diluent provide by the kit at 37 °C for 1 h, followed
by peroxidase-conjugated anti-pig IgGs (1/5,000; kindly gifted by Dr. E.
Tabarés). The optical density (OD) value was measured at 405 nm
within 5min of adding the stop solution. Diluent, washing solution and
stop solution are from the INGEZIM PPA DAS kit (Ingenasa).
2.8.2. Western blot
Cells infected with Ba71 V or E70 ASFV were washed at 16 hpi with
PBS and lysed in RIPA modified buffer (50mM Tris-HCl pH 7.5, 1%
NP40, 0.25% Na-deoxycolate, 150mM NaCl, 1 mM EDTA) supple-
mented with protease and phosphatase inhibitors cocktail tablets
(Roche). The protein concentration was determined by a Pierce BCA
Protein Assay kit (Thermo Scientific). Infected cell lysates (40 μg of
protein) or purified recombinant ASFV proteins were fractionated by
SDS-PAGE and transferred to Immobilon membranes (Amersham). The
membranes were incubated with sera from pigs immunized with var-
ious recombinant proteins: p54 (1/800), CD2v (1/800), p35 (1/400),
p15 (1/1000), then exposed to horseradish peroxidase-conjugated pig
secondary antibody (dilution 1/80,000), followed by chemilumines-
cence (ECL, Amersham Biosciences) detection by autoradiography.
2.8.3. Neutralization assays
Sera from non-immunized (pre-immune sera) and immunized (im-
mune sera) animals were incubated at 56 °C for 30min for inactivation
and diluted 1/8 using DMEM supplemented with 20% of FBS and
0.05% Tween-80. ASFV-Ba71 V virus produced as described above was
incubated with pre-immune or immune sera at 37 °C overnight. The
level of virus neutralization was analyzed by using three different
techniques: i) Confocal Laser Scanning Microscopy (CLSM): Vero cells
were infected at a MOI of 5 with ASFV previously incubated with 1/8
dilution of either pre-immune or immune sera for 30min at 37 °C; cells
were then prepared for CLSM and analyzed for viral entry by incubation
with an anti-p72 monoclonal antibody (17LD3, gifted by Ingenasa).
Detailed methods are described in Supplementary Section. ii)
Fluorescence Activating Cell Sorting (FACS): Vero cells were infected at
a MOI of 1 with ASFV previously incubated with 1/16 dilution of either
pre-immune or immune sera for 18 h at 37 °C; the percentage of cells
expressing the major viral capsid protein p72 was then determined. iii)
Virus titration: Vero cells were infected at a MOI of 4·10−4 fpu/ml for
72 h with ASFV previously incubated with 1/8 dilution of either pre-
immune or immune sera for 18 h at 37 °C, and virus titer was analyzed
in Vero cells.
2.8.4. IFN-γ secreting PBMCs (ELISPOT) and IFN-γ ELISA
Antigen-specific IFN-γ response was determined by enzyme-linked
immunospot (ELISPOT) assay, using anti-pig IFN-γ antibodies (P2G10
RUO or biotinylated anti IFN-γ P2C11 RUO, Becton Dickinson
Table 1
Groups of pigs in which studies on reactivity to p15, p35, p54 and CD2v-E
proteins +/- ASFV pcDNAs were achieved.
Group
(n= 5)
Antigens for immunization Individual number of pig
Recombinant Protein Plasmid DNA
1 A p15 - 1-01,1-0 2
p15 p72 1-03, 1-04, 1-05
1B p35 - 1-07, 1-31
p35 CD2v 1-08, 1-09, 1-10
1C p54 - 1-11, 1-12
p54 p32 1-13, 1-14, 1-15
1D CD2v-E - 1-16, 1-17
CD2v-E CP312R 1-18, 1-19, 1-20
1E
CD2v-E p72 1-21, 1-23, 1-24
1F
p15 p32 1-28, 1-29, 1-30
1G
p35 CD2v 1-33, 1-34, 1-35
1H
p54 CP312R 1-38, 1-39, 1-40
Table 2
Groups of pigs immunized with combinations of p15, p35, p54, p32 and p72
+/- specific DNA constructs.
Groups
(n= 5/G)
Antigens for vaccination Individual number of pig
Recombinant protein Plasmid : pcDNA3
2 A p72 2-40
p72 p72 2-36, 2-37, 2-38, 2-39
2B p72 2-35
p72 g5R 2-31, 2-32, 2-33, 2-34
2C p32 2-30
p32 p32 2-26, 2-27, 2-28, 2-29
2D p32 2-20
p32 g5R 2-21, 2-22, 2-23, 2-24
2E p15+p35+p54 2-19, 2-20
p15+p35+p54 CD2v 2-16, 2-17, 2-18
2 F p72 + p32 2-10
p72 + p32 CD2v 2-06, 2-07, 2-08,2-0 9
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Pharmingen) following manufacturer’s instructions (Mateu de Antonio
et al., 1998; Prussin and Metcalfe, 1995). Only PBMCs from the second
animal experiment were used for IFN-γ ELISPOT assay. Briefly, blood
from immunized pigs was collected into sodium heparin and peripheral
blood mononuclear cells (PBMCs) were isolated by 1.077 Ficoll-hy-
paque separation and suspended in RPMI-1640 (Thermo Fisher Scien-
tific) with 10% FBS (cellgro™) and antibiotic-antimycotic Solution
(Corning™). MultiScreenHTS IP 96 well filter plates (Millipore) were
coated with 5 μg/ml of anti-IFN-γ antibody (P2G10RUO) by incubating
at 4 °C overnight; afterwards plates were washed five times with sterile
PBS, and then blocked with 10% FBS for 2 h at 37 °C. PBMCs were
added to wells at a density of 2×105 cells/well. ASFV antigens were
added to the wells at a final concentration of 6 μg/ml for protein an-
tigens and 1 μg/ml for DNA plasmid/antigens, in duplicates. Con-
canavalin A (Con A) mitogen (6 μg/ml) was used as a positive control
and media alone was the negative control. Following 36 h incubation at
37 °C, plates were washed with PBS w/0.05% Tween 20 and 0.5 μg/ml
of biotinylated anti-IFN-γ antibody (P2C11 RUO) was added for 2 h at
room temperature. Afterwards plates were washed and Streptavidin-
HRP (BioLegend) in PBS with 0.5% FBS was added (1:2000 con-
centration). After incubation for 45min at room temperature, the plates
were washed with PBS and colorimetric staining was performed with
the NovaRED solution (Vector labs) according to manufacturer’s in-
structions; then the plates were allowed to dry overnight. The spots
were counted by using ImmunoSpot 5.0.3 software (Cellular Tech-
nology Limited (CTL)).
For IFN-γ ELISA test, PBMCs from immunized pigs of the second
animal experiment were isolated and stimulated with respective pur-
ified ASFV antigens or mitogen (Con A) as positive control. After 5 days
incubation at 37 °C with 5% CO2, supernatants were collected and
tested using the porcine specific IFN- γ ELISA test (Thermo Scientific)
according to the manufacturer’s procedures. Briefly, 50 μl of cell culture
supernatants were added and incubated at room temperature for 1 h.
After washing, biotinylated anti-pig IFN-γ antibody was added and in-
cubated at room temperature, followed by washing and Streptavidin-
HRP was added. After washing, TMB substrate solution was added for
30min and the reaction was stopped using the stop solution. The op-
tical densities (OD) were measured at 450 nm. The concentration of
IFN-γ was calculated using a standard provided by the manufacturer.
3. Results
3.1. Expression of recombinant ASFV proteins
Full-length ASFV p15, p35, p54, and p72 were expressed together
with His-tags in baculovirus. Expression of the tagged, full-length pro-
teins p15, p35, p54,p72, and the extracellular domain of the CD2v
protein (CD2v-E), was confirmed by Western blot (Fig. 1).
3.2. Evaluation of humoral immune responses after vaccination with ASFV-
recombinant proteins and pcDNAs (ELISA test)
The presence of specific antibodies against p15, p35, p54, CD2v-E,
p32 and p72 were analyzed in sera from animals immunized with these
proteins alone or in combination with specific pcDNAs, by ELISA and
Western blot. As shown in ELISA tests depicted in Fig. 2, specific an-
tibodies against the respective ASFV antigens were present in pig sera
after three immunizations, either using single-protein immunization
(Fig. 2A), or multiple protein immunization (Fig. 2B), as performed
during the second animal experiment.
Especially high responses were detected for proteins p15, p32 and
p72. Interestingly, pcDNA-CP312R appeared to slightly increase the
antibody response generated against CD2v-E and p54 ASFV proteins.
To assess whether the combination of several of the most antigenic
proteins was able to increase the level of specific antibodies, we de-
veloped the next animal experiment (Experiment 2), in which pigs were
immunized with either a mixture of p72+p32, or with a mixture of
p15+p35+p54 (Fig. 2B). Furthermore, pcDNA-CD2v was included in
combination with each of the protein cocktails, since DNA encoding the
N-terminal domain of CD2v has been previously shown to enhance the
immune response, when injected together with specific ASFV antigens
(Argilaguet et al., 2012). The results showed that p32 was strongly
recognized by sera from immunized animals, whereas p72 induced only
a moderate antibody response, (independently of containing pcDNA-
CD2v). These data reveal that p32 could be an important ASFV target
for immune responses in vivo. Finally, the sera from pigs immunized
with p15+p35+p54 reacted similarly against p35 or p54, with slightly
higher reactivity observed against p15 (Fig. 2B, lower panel).
3.3. Recognition of viral proteins in ASFV-infected cells by sera from
immunized pigs (Western blot)
Western blot was performed in order to study whether the anti-
bodies present in the sera of immunized pigs were able to recognize
ASFV-specific proteins in infected cells. As shown in Fig. 3, sera from
immunized pigs were tested against extracts from either Mock-infected
COS cells or Ba71Vor E70- COS infected cells during 16 h, as well as the
respective recombinant ASFV protein used for immunization of pigs. As
Fig. 3A shows, sera from pigs immunized with recombinant CD2v-E
protein recognized very well a pattern of bands ranking from about 25
to 75 kDa, most likely corresponding to various glycosylated isoforms of
CD2v (75 kDa), in agreement with previous reports (Perez-Nunez et al.,
2015). Furthermore, a band of approximately 100 kDa in ASFV-infected
cells, which is not present in extracts from mock-infected cells. This
100 kDa band corresponds to the expected size of the full-length CD2v
glycosylated protein (Perez-Nunez et al., 2015).
Sera from immunized pigs recognize recombinant p54 and p35
proteins in infected cells, (Figs. 3B and C) with molecular weights of
around 31 and 42 kDa respectively. However, antibodies present in the
sera of p35 immunized pigs were not able to recognize any specific
band in ASFV-infected COS cells (Fig. 3C). Sera from animals im-
munized with p54 protein strongly recognized a band of about 25 kDa
in cells infected with both ASFV isolates (Fig. 3B), as expected from the
size of the orf encoding for this viral protein. The pig sera against p15
recognized the recombinant protein, but did not react against ASFV-
infected cells (Fig. 3D). Sera from pigs immunized with p32 resulted in
a very strong and specific recognition of the recombinant protein
Fig. 1. Expression of recombinant proteins p15, p35, p54, CD2v-E, p72
and p32. A. Western blots were performed to confirm the expression of ASFV
proteins using anti-Histidine for p15, p35, p54, CD2v-E, p72 and p32 protein.
The respective protein was expressed 26 kDa for p15, 43 kDa for p35, 31 kDa for
p54, various isoform for CD2v-E, 79 kDa for p72, and 28 kDa for p32. Black
arrows denote the expressed recombinant proteins of interest. M=Protein
ladder.
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(Fig. 3E), revealing bands from 30, 32 and 34 kDa, putatively due to
phosphorylation as previously described (Prados et al., 1993), together
with a higher band that could represent a dimer of the p32 viral protein.
Importantly, the serum against p32 strongly recognizes a specific band
in the extracts corresponding to both Ba71 V and E70-infected cells,
which is not present in mock cells. Furthermore, the molecular weight
of this band exactly corresponds to 32 kDa, in concordance with the
Western blot profile seen with an in house p32-specific serum.
The sera from p72-immunized pigs were able to recognize the re-
combinant protein with a molecular weight corresponding to 72 kDa
(Fig. 3F), in concordance with Fig. 1. A weak band was detected in
cellular extracts infected with Ba71 V, most likely indicating that p72
recombinant protein did not induce a strong specific antibody response.
3.4. Serum from immunized pigs neutralize ASFV infection in vitro
To analyze the presence of ASFV neutralizing antibodies in the sera
of immunized pigs, we used three different methods: (i) inhibition of
ASFV entry after 30min of viral adsorption, (ii) percentage of inhibition
of p72 expression after 16 hpi of ASF infection, determined by FACS
and (iii) inhibition of the viral production by plaque titration at 48 hpi.
A detailed description of these methods is provided in the Materials and
Methods section and in the Supplementary Materials.
First, (i) we chose the sera from pigs immunized with the combi-
nation p15+pcDNA-p72, since both of these products are abundantly
present in the virion (Simon-Mateo et al., 1997), thus specific anti-
bodies against these proteins could neutralize the virus entry. As shown
in Fig. 4, the specific immune serum against p15+pcDNA-p72 partially
impaired the viral entry in Vero cells. This impairment was further
quantified showing that virion particles, identified with a specific
monoclonal antibody anti p72, were found only in about 45% of the
cells incubated with immune serum, compared to 100% cells infected
after incubation with pre-immune sera. Next, (ii) we further in-
vestigated the neutralization ability of several sera by measuring the
expression of the ASFV p72 protein by FACS analysis after 16 hpi.
To achieve this, we first incubated the selected sera together with
the virus and then we added this mix to Vero cells. To set up the
method, a hyperimmune serum from an ASFV-infected pig (previously
developed in our lab), induced a reduction of ASFV infection in Vero
cells of around 80% when compared to the pre-immune serum
(Supplementary Fig. 1). Neutralization results using sera from im-
munized pigs by FACS analysis are shown in Supplementary Fig. 2, and
Fig. 2. Antibody detection in sera of pigs immunized with
the p15, p35, CD2v-E, p54, p32 and p72 ASFV proteins by
ELISA tests. Sera from immunized pigs with (A) one single
viral protein or (B) multiple viral proteins in combination with
viral DNA, were tested by ELISA using respective single anti-
gens. Two dilutions of sera were tested in each case: 1/20
(black bars) or 1/200 (grey bars). Sera from non-immunized
pigs were used as controls. Values of optical density at 405 nm
were measured. Experimental group of each combination of
protein-DNA is shown. Average of three or two animal sera
from each group (according to Tables 1 and 2) with standard
error is shown.
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in Fig. 5A. Specifically, sera from pigs immunized with p15 protein in
combination with pcDNA-p32, slightly neutralized ASFV (Fig. 5A),
whereas sera from pigs immunized with p35 in combination with
pcDNA-CD2v showed a more effective ASFV neutralizing ability of
about 20%. Furthermore, we observed that sera from animals im-
munized with CD2v-E protein and pcDNA-CP312R induced a re-
producible, although slight, neutralization compared with the pre-
immune sera (Fig. 5A).
In order to verify the neutralization results showed above, we tested
the ability of the hyperimmune sera to neutralize ASFV infection in vitro
by analyzing viral plaque formation (Fig. 5B). The sera from pigs im-
munized with combinations of protein and pcDNAs (p15+pcDNA-p32,
p35+ pcDNA-CD2v, and CD2v-E+pcDNA-CP312R) were found to
induce the higher levels of neutralization, showing a decrease of viral
plaque formation compared to pre-immune sera, thus confirming the
data shown in Fig. 5A. Taken together, these results show that selected
combinations of viral proteins and pcDNAs synergistically induce an-
tibodies that can partially neutralize ASFV infectivity in vitro.
3.5. IFN-γ secreting PBMCs
IFN-γ secreting cells in PBMCs from vaccine groups of the second
animal experiment were analyzed by ELISPOT (Fig. 6A). PBMCs were
isolated from blood collected from immunized pigs at day 49 dpi. The
PBMCs were stimulated with the same antigens as used for in vivo im-
munization. Fig. 6A shows that IFN-γ secreting cells specific for the
respective ASFV antigens were barely present in the blood of im-
munized pigs. The best proteins or protein combinations for the in-
duction of IFN-γ were p72 (34.9 per 200,000 cells) and p15 (35.3 per
200,000 cells), whereas neither combination of p72+p32 nor
p15+p35+p54 proteins was able to increase the number of IFN-γ se-
creting PBMCs.
Fig. 6B shows the concentration of IFN-γ after in vitro re-stimulation
of PBMCs from immunized pigs using the respective single and com-
binations of proteins, as measured by a commercial ELISA kit. IFN-γ
was detected in supernatants of PBMCs from pigs immunized and re-
estimulated with p72 (73.4 pg/ml) and p72+p32 proteins mixture,
(62.6 pg/ml), whereas combination of p15+p35+ p54 proteins did not
Fig. 3. Recognition of viral proteins expressed during ASFV infection by sera from immunized animals. Sera from immunized animals with A) CD2vE
protein+pcDNACP312R (pig 1–18), B) p54 protein+pcDNACP312R (pig 1–39), C) p35 protein+ pcDNACD2v-E (pig 1-08), D) p15 protein (pig 1-02), E) p32
protein+pcDNA p32 (pig 2–27) and F) p72 protein+ pcDNAp72 (pig 2–36) were used to detect viral proteins in COS-7 cells extracts infected for 16 h with either
Ba71 V or E70 ASFV strains by Western blot analysis(open arrows). The specific recombinant proteins used to immunized animals were also analyzed (close arrows).
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increase secreted IFN-γ, consistent with the results obtained in Fig. 6A.
4. Discussion
Several reports have pointed out that both humoral and cellular
responses are involved in ASFV protection (Gomez-Puertas et al., 1996;
King et al., 2011; Leitao et al., 2001; Oura et al., 2005; Ruiz Gonzalvo
et al., 1986b; Stone and Hess, 1967; Zsak et al., 1993). Since ASFV
encodes for more than 150 viral proteins, the identification of in-
dividual or combinations of viral antigens that could elicit a protective
immune response against infection is rather challenging. Experimental
immunization protocols are key to analyze specific immune mechan-
isms, and for the development of an effective ASF vaccine. Based on
previous studies on the function of several ASFV proteins (Andres et al.,
2002; Argilaguet et al., 2012; Neilan et al., 2004; Perez-Nunez et al.,
2015; Quintas et al., 2017; Rodriguez et al., 1993; Sanchez et al., 2013)
we designed an immunization format using combinations of selected
ASFV recombinant proteins and plasmids encoding ASFV-specific
pcDNAs. The rationale behind combining genotype I and II antigens
would provide a potential means to expand cross-protection, which
Fig. 4. Blockage of viral entry by pig 1-03 serum. After virus incubation (60 min at 37 ºC) with pre-immune or immune sera from a pig immunized with p15 +
pcDNA-p72 (pig number 1-03). 100.000 Vero cells per coverslip were infected with Ba71V 5UFP/cell (500.000 virions/coverslip) for 30 min at 37 ºC, and then
washed and fixed for immunostaining. Anti p72 antibody (17LD3) was added to detect virus particles and cell and nuclei were stained with phalloidin and Topro-3,
respectively. A number of 100 cells/sample (non-immune or immune sera), were analyzed for p72 immune fluorescence after infection with 5x102 virions. Finally,
the enclosed graphic represent the percentage of viral particles visualized into the cells, based on the data shown in CLSM Image.
Fig. 5. Neutralization of ASFV infection by sera. A) Ba71 V
was pre-incubated with either pre-immune sera (black bars) or
immune sera (grey bars) from the different groups of im-
munization, and used to infect Vero cells. After 16 hpi the
percentage of p72 expression was determined by FACS using a
p72-specific MoAb antibody (17LD3). B) Ba71 V was pre-in-
cubated with either pre-immune sera (black bars) or immune
sera (grey bars) and used to infect Vero cells. Viral production
was measured at 5 days after infection by plaque assay and
represented as a percentage relative to the virus titer in im-
mune sera samples corresponding to pre-immune sera sam-
ples. Experimental group of each combination of protein-DNA
is shown according to Table 1. Average of two animal sera
from each DNA-protein combination with standard error is
shown. According to Table 1: 1 A: animals 1, 2, 4 and 5; 1B:
animals 7, 8, 9 and 31; 1C: animals 11, 12, 13 and 14; 1D:
animals 16, 17, 18 and 19; 1E: animals 21 and 23; 1F: animals
28 and 29; 1H: animals 38 and 39.
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could then be tested in subsequent challenge experiments.
The immune responses induced in pigs were tested by analyzing the
ability of the sera to recognize the proteins used as antigens, the ability
of immune sera to neutralize ASFV infection in vitro, and by de-
termining the ASFV-specific IFN-γ induction from immune PBMCs.
The results indicate that most of the pcDNAs used in combination
with proteins in vaccination experiences, did not importantly affect the
antibody response against recombinant proteins. There are few excep-
tions, such as pcDNA-p32, which combined with p15 protein, reduced
the level of antibodies compared to the immunization with p15 protein
alone; and pcDNA-CP312R, which appeared to slightly increase the
antibody response generated against CD2v-E and p54 ASFV proteins.
These last results indicate either that pcDNA-CP312R encodes a product
efficiently recognized by the humoral immune response, or that the
response against both proteins and the plasmid-encoded product acts
synergistically. Finally, it is clear that the values obtained against either
p35 alone or in combination with pcDNA-CD2v were low in general.
The ELISA tests demonstrated that sera from immunized pigs were
able to recognize the recombinant protein (s) used as antigens in each
vaccination., Recombinant protein p35 was identified as the weaker
immunogen, whereas pigs immunized with the ASFV p15 or p32 re-
combinant proteins developed the highest antibody response
(OD > 2.0); pigs immunized with p72, p54 and CD2v recombinant
proteins also developed good antibody measures. These data agree with
reports pointing to these proteins as important antigens eliciting strong
immune responses (Argilaguet et al., 2012; Gomez-Puertas et al., 1998;
Neilan et al., 2004; Reis et al., 2007; Ruiz-Gonzalvo et al., 1996), fur-
ther targeting CP312R as a new interesting antigenic factor.
Furthermore, we found that serum antibodies from animals im-
munized with recombinant pCD2-E+pcDNACP312R, recombinant
p54 and recombinant p32+pcDNAp32, were able to recognize by
Western blot extracts both of the respective recombinant protein and
the specific proteins expressed during the infection with either Ba71 V
or E70 ASFV strains. However, sera from animals immunized with
recombinant p15, with recombinant p35+pcDNACD2v-E or with re-
combinant p72 recombinant+ pcDNAp72, were only able to recognize
the specific recombinant protein. This last result suggests that con-
formational modifications of these antigens could occur during the in-
fection and/or that the viral proteins epitopes are not well recognized
by the antibodies generated in the sera.
Relatively few reports have described the mechanism of ASFV
neutralization, most likely because the most accepted hypothesis is that
ASFV induces antibodies that are not fully neutralizing in vitro or pro-
tective in vivo (Escribano et al., 2013; Hess, 1981; Vinuela, 1985).
However, several laboratories have demonstrated that ASFV can be
partially neutralized by both monoclonal antibodies (Sanz et al., 1985)
and immune sera from convalescent swine, infected with homologous
or heterologous ASFV strains (Borca et al., 1994; Ruiz Gonzalvo et al.,
1986a, b; Zsak et al., 1993). Using a neutralization assay previously
established in our laboratory, we show here that serum against p35 in
combination with pcDNA-CD2v partially neutralized ASFV in vitro
(about 20% reduction in plaques). In a similar way, when CD2v was
used as protein in combination with pCDNA-CP312R to immunize pigs,
the sera neutralized virus infection in vitro with about 10% reduction.
These results were confirmed by FACS and by titration of viral lysis
plates. In contrast, pig antibodies produced against various pcDNAs
alone, such as pcDNA-p72, pcDNA-p32, pcDNA-CD2v or cDNA-
CP312R, did not neutralize or only slightly neutralized ASFV infection
(data not shown). Our data suggest a putative role for antibodies
against structural p35 and CD2v proteins, and for pcDNAs encoding
p32, CD2v and CP312R, in ASFV neutralization.
It is well known that plasmid DNA can possess its own adjuvant
activity due to the presence of unmethylated CpG motifs in certain base
contents (Bode et al., 2011). Furthermore, work from (Argilaguet et al.,
2012), showed that fusion of the extracellular domain of the ASFV
Hemagglutinin (sHA) to p54 and p30, exponentially improved both the
humoral and the cellular responses induced in pigs after DNA im-
munization, but did not confer protection against lethal challenge with
Fig. 6. ELISPOT showing IFN-γ-secreting PBMC after pro-
teins/pcDNAs re-stimulation. A) Number of responding
PBMCs derived from immunized piglets on 49 dpi and re-sti-
mulated with indicated viral proteins and pcDNAs. B) IFN-γ
concentration measured by a commercial ELISA kit as de-
scribed in the Materials and Methods section. ConA: con-
canavalin A. Standard error is presented as bars.
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the virulent E75 ASFV-strain. However, these viral antigens (p54, p30,
and the CD2v extracellular domain) fused to ubiquitin correlated with
the presence of a large number of hemagglutinin-specific CD8(+) T
cells in blood and partial protection against virulent challenge.
Nevertheless, the mechanism of the observed synergism between
specific ASFV proteins and pcDNAs-encoding ASFV factors is not clear
at this time, but one hypothesis is that the pcDNA triggers some non-
specific immune responses, which in term boost specific response to the
proteins.
Regarding IFN-γ production, it is noticeable that p72 protein was
found the main inducer of this cytokine, both in the number of PBMC
able to produce it and in the amount of IFN-γ produced by responsive
cells. However, we found that p15-specific PBMCs produced relatively
low amounts of IFN-γ. Taken together, these results suggest that p72, a
strong antibody-inducing viral factor, was found to be able to stimulate
IFN-γ-producing PBMC populations. Furthermore, p72 in combination
with p32, another potent viral antigen, induced a relatively low po-
pulation of specific PBMCs, which however produced measurable
amounts of IFN-γ.
In conclusion, our work presents data of the immunogenicity of
several ASFV antigens, by immunizing pigs with both recombinant
proteins alone or in combination with pcDNAs-encoding viral genes. In
absence of efficient ASFV vaccines, and LAVs being the only protecting
alternative against this pathogen, our data add information about viral
antigen-specific responses and would contribute to the generation of
future and safer ASFV subunits vaccines, providing information to as-
sess the potential of the analyzed combinations in in vivo experiences of
challenge against ASFV virulent strains in the near future.
5. Conclusions
- Immunization of groups of pigs with combinations of selected ASFV
viral DNA and recombinant proteins resulted in induction of specific
antibodies.
- Ability of antibodies present in sera from some of the immunized-
pigs to neutralize infection in vitro confers relevance to specific viral
antigens used in the immunization.
- Results from IFN-γ ELISpots demonstrated activation of the cell-
mediated immune response by immunization of pigs with combi-
nation of several viral DNAs+proteins.
- The information presented here can help to the development of
future subunit vaccines against ASFV.
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